摘要
目的:了解肿瘤内科住院患者非甾体抗炎药的使用情况,为进一步规范合理使用非甾体抗炎药提供依据。方法:回顾性分析2019年山东省千佛山医院肿瘤内科住院患者使用非甾体抗炎药的相关数据,统计患者基本信息、胃肠道和心血管危险因素以及非甾体抗炎药的使用情况、不良反应发生情况。结果:共纳入205例患者。非甾体抗炎药临床使用的主要问题包括,(1)未按照胃肠道风险管理使用非甾体抗炎药(占35.61%,73/205);(2)未按照心血管风险管理使用非甾体抗炎药(占40.49%,83/205);(3)用法、用量不适宜(占4.39%,9/205);(4)疗程不适宜(占7.80%,16/205)。结论:肿瘤内科非甾体抗炎药的使用存在较多不合理现象,主要问题是未重视患者的胃肠道和心血管危险因素分层管理,需加强监管和干预,提升合理用药水平。
OBJECTIVE:To investigate the application of nonsteroidal anti-inflammatory drug(NSAID).METHODS:To retrospectively analyze the data related to the application of NSAID on inpatients in department of medical oncology in Shandong Provincial Qianfoshan Hospital in 2019,to collect the basic information,gastrointestinal and cardiovascular risk factors,application of NSAID and incidences of adverse drug reactions of patients.RESULTS:A total of 205 patients were involved.Main problems in the clinical application of NSAID included:(1)NSAID were not used in accordance with gastrointestinal risk management(35.61%,73/205);(2)NSAID were not used in accordance with cardiovascular risk management(40.49%,83/205);(3)improper usage and dosage(4.39%,9/205);(4)inappropriate course of treatment(7.80%,16/205).CONCLUSIONS:There are some irrational application of NSAID in department of medical oncology,and the main problem is the lack of attention to the hierarchical management of gastrointestinal and cardiovascular risk factors in patients,and the supervision and intervention are needed to improve rational medication.
作者
高榕荫
刘斐烨
徐巍
GAO Rongyin;LIU Feiye;XU Wei(Dept. of Pharmacy, the First People’s Hospital of Changzhou/the Third Affiliated Hospital of Soochow University, Jiangsu Changzhou 213003, China;Dept. of Pharmacy, Shandong Provincial Qianfoshan Hospital, Shandong Jinan 250014, China;School of Pharmacy, Shandong University, Shandong Jinan 250012, China)
出处
《中国医院用药评价与分析》
2020年第8期996-1000,共5页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
肿瘤内科
非甾体抗炎药
胃肠道风险
心血管风险
合理用药
Medical oncology
Nonsteroidal anti-inflammatory drugs
Gastrointestinal risk factors
Cardiovascular risk factors
Rational drug application